JPRN-jRCTs041210046已完成2 期
The Evaluation of Efficacy and Safety of Additional Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the 2nd Exploratory Clinical Study in Patients Requested Medical Care - RECIPE-2 Study
Katsuno Masahisa0 个研究点目标入组 5 人开始时间: 2021年8月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients with definite CIDP diagnosed according to the modified diagnostic criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) (2010) by the time of enrollment in the study
- •2. Patients with positive serum IgG4 autoantibody (NF-155) confirmed by the time of enrollment in the study
- •3. Patients with refractory CIDP not responding adequately to treatment with corticosteroids for 12 weeks and intravenous immunoglobulin therapy (IVIg) for 8 weeks by the time of enrollment in the study, or those who are unable to administer or continue corticosteroids and IVIg
- •4. Patients with total adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale scores of 2 to 8 at enrollment
- •5. Patients meeting one of the following conditions:
- •1) Patients received rituximab (genetical recombination) IV infusion for CIDP treatment
- •2) Patients received rituximab (genetical recombination) or placebo IV infusion in RECIPE trial participant
- •6. Patients aged 20 years or older at informed consent
- •7. Patients who give their voluntary written consent after having received adequate information on this study
排除标准
- •1.Patients with disease meeting one of the following exclusion criteria defined in the modified EFNS/PNS diagnostic criteria (2010).
- •1)Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy Hereditary demyelinating neuropathy
- •2)Prominent sphincter disturbance
- •3)Diagnosis of multifocal motor neuropathy
- •4)IgM monoclonal gammopathy with high antibody titers to myelin-associated glycoprotein
- •5)Other causes for demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy
- •PNS lymphoma and amyloidosis may occasionally have demyelinating features
- •2.Patients who have started or have increased the dose of corticosteroids for CIDP within 12 weeks prior to the enrollment
- •3.Patients who have started or have increased the dose of IVIg within 8 weeks prior to the enrollment
- •4.Patients who have undergone plasmapheresis within 8 weeks prior to the enrollment or patients with refractory disease not responding adequately to 8 weeks of plasmapheresis (plasma exchange or double-filtration plasmapheresis)
- •5. Patients who have started or have increased the dose of an immunosuppressant (azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, interferon-alpha, interferon-beta, etanercept, methotrexate, mitoxantrone, alemtuzumab, cladribine, tacrolimus, fingolimod) within 12 weeks prior to the enrollment
- •6.Patients who have undergone hematopoietic stem cell transplant prior to the enrollment
- •7.Patients who have used rituximab (genetical recombination) within 6 months prior to the enrollment
- •8.Patients who have participated in another clinical study within 3 months prior to the enrollment (enrollment is allowed for those participating in a clinical study in the range of Indications or Dosage and Administration in Japan) or patients who are participating in another study
- •9. Patients with poorly controlled diabetes
- •10.Patients who have or are suspected of having an active infection (infection requiring treatment with systemic antimicrobial, antifungal, or antiviral agents) at the time of the enrollment
- •11.Patients tested positive for HBs antigen, HBs antibody, HBc antibody, and/or HCV antibody (patients with positive hepatitis B surface antibody or core antibody can be enrolled when a hepatitis B virus-DNA test is negative [below the limit of detection], and hepatitis B virus-DNA and aspartate/alanine transaminase levels are monitored at fixed intervals), or patients with positive HIV antibody or HTLV-1 antibody at the time of the enrollment
- •12.Patients with leukopenia (less than 2,000 /mm3), neutropenia (less than 1,000 /mm3), or lymphopenia (less than 500 /mm3) at the time of the enrollment
- •13.Patients with a history of serious hypersensitivity or anaphylactic reaction to one of the ingredients in the investigational drug or murine protein-containing products
- •14.Patients with serious comorbidity (e.g., hepatic, renal, cardiac, lung, hematologic, or brain disease)
- •15.Female patients who are pregnant, lactating, or potentially pregnant, or patients who are not willing to use contraceptive measures during the study period
- •16.Patients who are judged to be unsuitable by the investigator or a sub-investigator
研究者
相似试验
招募中
2 期
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.IRCT20090613002027N21Mazandaran University of Medical Sciences60
已完成
不适用
Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapyType 2 diabetesJPRN-UMIN000010849Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine40
尚未招募
3 期
Effectiveness of Unani add-on therapy in preventing the disease severity of COVID-19 infectioCTRI/2020/12/029575Central Council for Research in Unani Medicine
招募中
不适用
Assessment of the efficacy and safety of accessory nerve reconstruction using nerve regeneration inducing tube in neck dissection for patients with head and neck cancer - A Prospective Multicenter Clinical StudyHead and neck cancerJPRN-UMIN000032336Yokohama City University12
进行中（未招募）
1 期
se of an antidiabetic drug (Empagliflozin) to lower the blood level of 1,5-anhydroglucitol in patients deficient in the glucose-6-phosphate transporter (GSD1b) and the phosphatase G6PC3, both of the endoplasmic reticulum, to treat their recurrent infections by normalizing their blood neutrophil counts. Neutrophils are the most abundant white blood cells in our blood that are essential to help fighting infections. 1,5-anhydroglucitol is a sugar derivative with no known function.(1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Storage Disease type 1b due to a deficiency in the glucose-6-phosphate transporter (G6PT / SLC37A4) of the endoplasmic reticulum.EUCTR2018-004191-35-BECliniques universitaires Saint-Luc5